Replies to post #19074 on Mymetics Corp (MYMX)

[Work Harder]

It's what Winter Dala Lama

wants

LOL

but it will probably be w/ Anergis

Knock Knock

Amy

[Work Harder]

Following a May 2013 research alliance between the companies focused on respiratory allergy therapies, immunotherapy specialist Stallergenes has partnered with DBV Technologies to develop and commercialise a treatment for birch pollen allergy using DBV’s Viaskin® epicutaneous drug delivery technology, which modulates the immune response to allergens...

http://www.pharmadeals.net/journal/pharmadealsreview/details/1987

https://au.linkedin.com/in/eric-potier-a345ab192/en-us?challengeId=AQHonmKHNvCy_gAAAXMvKry4LvMwoMKMMdRtT8MjL_VTuS6tymf0udNwx75pzVMsrdy88uJU68cvtLfZKPhdfisBVjhJFOLB8A&submissionId=af0250cc-75d2-1f16-5b93-e0a5e07d086a

[Work Harder]

We want to see some of these

https://www.sec.gov/Archives/edgar/data/1613780/000119312514348118/d760135df1.htm

LOL

Interesting

https://www.crunchbase.com/organization/dbv-technologies/timeline/timeline

DBV Technologies Announces Closing of Global Offering

February 4, 2020

Goldman Sachs and Citigroup acted as joint lead book-running managers for the Global Offering. JMP Securities acted as lead manager for the Global Offering. H.C. Wainwright & Co. and Kempen & Co acted as co-managers for the Global Offering.

A registration statement on Form F-3 relating to the securities to be issued in the Global Offering was filed with the Securities and Exchange Commission and was declared effective on October 1, 2019.

https://markets.businessinsider.com/news/stocks/dbv-technologies-announces-closing-of-global-offering-1028873882#

[Work Harder]

Two of the leaders responsible for regulatory and product development at DBV Technologies are set to leave the company this month.

Both men were central to the development of Viaskin Peanut and its submission to FDA

Viaskin Peanut has hit bumps in the road on its path to market, from its inability to hit the primary endpoint in phase 3 through to DBV’s need to pull the original filing after the FDA identified gaps in the manufacturing and quality control sections. Three of the people involved in those events, Ruban, Martin and former CMO Lucia Septién-Velez, have left DBV this year.

DBV is yet to replace any of the departing executives, although it did hire ex-Alexion Pharmaceuticals EVP Julie O’Neill to direct “all product development, manufacturing, supply chain, quality assurance and end-to-end process optimization” at the start of the year. O’Neill will take on Martin’s primary responsibilities.

Given the mess DBV made of the original filing, the overhaul of the regulatory leadership could be seen as a positive. But it leaves DBV without the experience of several people who were central to the development of Viaskin Peanut and with unfilled gaps in its leadership team.

DBV needs the new-look team to nail the filing this time around. With DBV planning to refile for FDA approval months before its money runs out in the fourth quarter, there is little margin for error, particularly as the earlier setbacks have diminished its ability to raise more cash.

Shares in DBV have risen by more than 60% since the stock cratered following the filing withdrawal late last year but remain well down on the heights they scaled before the clinical and regulatory setbacks.

https://www.fiercebiotech.com/biotech/dbv-loses-regulatory-r-d-execs-ahead-peanut-drug-refile

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155790630

[Work Harder]

Robbins Arroyo LLP: DBV Technologies S.A. (DBVT) Sued for Misleading Shareholders

https://www.businesswire.com/news/home/20190204005687/en/Robbins-Arroyo-LLP-DBV-Technologies-S.A.-DBVT

According to the complaint, in February 2018, DBV announced that the U.S. Food and Drug Administration ("FDA") agreed that the efficacy and safety data for DBV's drug, Viaskin Peanut, supported the submission of a Biologics License Application ("BLA"). In October 2018, DBV stated that the company submitted its BLA, calling it a "significant step forward for those families living with peanut allergy." It came as a surprise to investors when, less than two months later, DBV announced that it voluntarily withdrew its BLA because the FDA determined that the level of detail for manufacturing procedures and quality controls was insufficient. On this news, DBV shares plummeted nearly 60% to close at $5.76 per share on December 20, 2018.

[Work Harder]

What's going on here ?

https://fttoolkit.co.uk/NEDD/qualify/q_qualify.html

LOL

[Work Harder]

Amy wouldn't let them in

so the nasty about to get done ?

Oh my

Global Head office Stallergenes Greer Ltd Tower bridge House St Katharine's Way London

Headquartered in Boston, Massachusetts with locations in Lenoir, North Carolina and San Diego California, Stallergenes Greer's business in the United States is part of a leading global biopharmaceutical company specializing in the development and commercialization of allergy immunotherapy (AIT) products and services

https://qualifications.pearson.com/en/about-us/about-pearson/our-history.html

It began as long ago as 1836, when a royal charter gave the University of London its first powers to conduct exams and confer degrees on its students.

& Csti looking to pick up shares

[Work Harder]

Ronald needs to explain today's events

or make this B go dark

It's beyond rode hard & put up wet

Gives need meaning to wore out

I sure hope he got something out of the evaluation part of that class

b/c it sure isn't showing

as is

[Work Harder]

If Amy even thinks

I'm going to let VC step on Hugo's day

Then VC has another thing coming

:}

[Work Harder]

Mr K's big day

Did VC just try to step on that

He did & didn't take ownership of it

Conflict of interest w/ Lonza fella & Swiss Topical

both have or have had patents w/ Mymx

Like AF does in the US w/ others

No doubt about that

Maybe Mr K had that coming b/c skin is as thick as water

but

We are owed an explantion

Sure as every post will begin in bold

w/

BLACKE EYE OF BIOPOLE

SOON

[Work Harder]

Let me make this easy for all

Question # 1

Do you have anything that will make significant high side potential in a timely fashion

SOON in his own words again in a way

Question # 2

Have you had any offers to buy your company, in the past or recently

Both can be answered

Then # 3 afterwards

b/c cure is a term that should not be played with

:}

[Work Harder]

Wread up Bro

So this guy

Pieter Leentvaar

has ties to VC's CFO ?

That works for Catalent now

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156604050

You think Stallergenes has a fella like that

&

others

:}

[Work Harder]

You're telling me I'm wrong

on Mr K's options

b/c I'm telling you

I'M NOT

[Work Harder]

Now yu know what I meant by what I meant

That you have some work to do

last Friday

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156657915

Kuros shares are expected to make up a total of approximately 15.5% of the outstanding share capital of the combined company post-closing. Options and warrants of around 8.6% of the outstanding share capital post-closing are expected to be in the money at closing.

You make no mistake about this friend

It's on

[Work Harder]

086 @ 303 is

26,058,000

Profit on debt or equal

in general numbers

:}

[Work Harder]

If they can pick up Mymetics

No need to license b/c they would own the Mymetics part of the patent

plus 2nd gen Hiv (2nd yr of Nih funding) & Malaria that could be coming before long

plus oncology ?

It's getting interesting